RT Journal Article
T1 Similarities between acylcarnitine profiles in large for gestational age newborns and obesity
A1 Sánchez Pintos, Paula
A1 Castro, María José de
A1 Roca, Iria
A1 Rite, Segundo
A1 López Pérez, Miguel A.
A1 Couce Pico, María Luz
AB Large for gestational age (LGA) newborns have an increased risk of obesity, insulin resistance, and metabolic syndrome. Acylcarnitine profiles in obese children and adults are characterized by increased levels of C3, C5, and certain medium-chain (C12) and long-chain (C14:1 and C16) acylcarnitines. C2 is also increased in insulin-resistant states. In this 1-year observational study of 2514 newborns (246 LGA newborns, 250 small for gestational age (GA) newborns, and 2018 appropriate for GA newborns), we analyzed and compared postnatal acylcarnitine profiles in LGA newborns with profiles described for obese individuals. Acylcarnitine analysis was performed by tandem mass spectrometry on dried-blood spots collected on day 3 of life. LGA newborns had higher levels of total short-chain acylcarnitines (p < 0.001), C2 (p < 0.01) and C3 (p < 0.001) acylcarnitines, and all C12, C14, and C16 acylcarnitines except C12:1. They also had a higher tendency towards carnitine insufficiency (p < 0.05) and carnitine deficiency (p < 0.001). No significant differences were observed between LGA newborns born to mothers with or without a history of gestational diabetes. This novel study describes a postnatal acylcarnitine profile in LGA with higher levels of C2, C3, total acylcarnitines, and total short-chain acylcarnitines that is characteristic of childhood and adult obesity and linked to an unhealthy metabolic phenotype.
PB Nature Publishing Group
SN 2045-2322
YR 2017
FD 2017
LK http://hdl.handle.net/10347/22399
UL http://hdl.handle.net/10347/22399
LA eng
NO Sánchez-Pintos, P., de Castro, M., Roca, I. et al. Similarities between acylcarnitine profiles in large for gestational age newborns and obesity. Sci Rep 7, 16267 (2017). https://doi.org/10.1038/s41598-017-15809-4
NO Dr Lopez has received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 281854 -the ObERStress project, Xunta de Galicia (2015-CP079 and 2016-PG068), MINECO co-funded by FEDER (SAF2015-71026-R and BFU2015-70454-REDT/Adipoplast)
DS Minerva
RD 23 abr 2026